205 related articles for article (PubMed ID: 18585004)
1. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes.
Xie P; Tian C; An L; Nie J; Lu K; Xing G; Zhang L; He F
Cell Signal; 2008 Sep; 20(9):1671-8. PubMed ID: 18585004
[TBL] [Abstract][Full Text] [Related]
2. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
[TBL] [Abstract][Full Text] [Related]
3. MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output.
Chen L; Li Z; Zwolinska AK; Smith MA; Cross B; Koomen J; Yuan ZM; Jenuwein T; Marine JC; Wright KL; Chen J
EMBO J; 2010 Aug; 29(15):2538-52. PubMed ID: 20588255
[TBL] [Abstract][Full Text] [Related]
4. The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation.
Yoh SM; Lucas JS; Jones KA
Genes Dev; 2008 Dec; 22(24):3422-34. PubMed ID: 19141475
[TBL] [Abstract][Full Text] [Related]
5. The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage.
Magrini R; Russo D; Fronza G; Inga A; Menichini P
J Cell Biochem; 2007 Apr; 100(5):1276-87. PubMed ID: 17063487
[TBL] [Abstract][Full Text] [Related]
6. Activated p53 suppresses the histone methyltransferase EZH2 gene.
Tang X; Milyavsky M; Shats I; Erez N; Goldfinger N; Rotter V
Oncogene; 2004 Jul; 23(34):5759-69. PubMed ID: 15208672
[TBL] [Abstract][Full Text] [Related]
7. BCL11B tumor suppressor inhibits HDM2 expression in a p53-dependent manner.
Obata M; Kominami R; Mishima Y
Cell Signal; 2012 May; 24(5):1047-52. PubMed ID: 22245141
[TBL] [Abstract][Full Text] [Related]
8. SMAR1 forms a ternary complex with p53-MDM2 and negatively regulates p53-mediated transcription.
Pavithra L; Mukherjee S; Sreenath K; Kar S; Sakaguchi K; Roy S; Chattopadhyay S
J Mol Biol; 2009 May; 388(4):691-702. PubMed ID: 19303885
[TBL] [Abstract][Full Text] [Related]
9. The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability.
D'Arcy P; Maruwge W; Ryan BA; Brodin B
Mol Cancer Res; 2008 Jan; 6(1):127-38. PubMed ID: 18234968
[TBL] [Abstract][Full Text] [Related]
10. H3K36 trimethylation mediated by SETD2 regulates the fate of bone marrow mesenchymal stem cells.
Wang L; Niu N; Li L; Shao R; Ouyang H; Zou W
PLoS Biol; 2018 Nov; 16(11):e2006522. PubMed ID: 30422989
[TBL] [Abstract][Full Text] [Related]
11. The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters.
Al Sarakbi W; Sasi W; Jiang WG; Roberts T; Newbold RF; Mokbel K
BMC Cancer; 2009 Aug; 9():290. PubMed ID: 19698110
[TBL] [Abstract][Full Text] [Related]
12. Regulation of p53 activity through lysine methylation.
Chuikov S; Kurash JK; Wilson JR; Xiao B; Justin N; Ivanov GS; McKinney K; Tempst P; Prives C; Gamblin SJ; Barlev NA; Reinberg D
Nature; 2004 Nov; 432(7015):353-60. PubMed ID: 15525938
[TBL] [Abstract][Full Text] [Related]
13. Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death.
Rosso M; Polotskaia A; Bargonetti J
Oncotarget; 2015 Oct; 6(33):34573-91. PubMed ID: 26416444
[TBL] [Abstract][Full Text] [Related]
14. H3K36 histone methyltransferase Setd2 is required for murine embryonic stem cell differentiation toward endoderm.
Zhang Y; Xie S; Zhou Y; Xie Y; Liu P; Sun M; Xiao H; Jin Y; Sun X; Chen Z; Huang Q; Chen S
Cell Rep; 2014 Sep; 8(6):1989-2002. PubMed ID: 25242323
[TBL] [Abstract][Full Text] [Related]
15. The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression.
West LE; Roy S; Lachmi-Weiner K; Hayashi R; Shi X; Appella E; Kutateladze TG; Gozani O
J Biol Chem; 2010 Nov; 285(48):37725-32. PubMed ID: 20870725
[TBL] [Abstract][Full Text] [Related]
16. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription.
Ohkubo S; Tanaka T; Taya Y; Kitazato K; Prives C
J Biol Chem; 2006 Jun; 281(25):16943-16950. PubMed ID: 16624812
[TBL] [Abstract][Full Text] [Related]
17. HDM2 impairs Noxa transcription and affects apoptotic cell death in a p53/p73-dependent manner in neuroblastoma.
Shi Y; Takenobu H; Kurata K; Yamaguchi Y; Yanagisawa R; Ohira M; Koike K; Nakagawara A; Jiang LL; Kamijo T
Eur J Cancer; 2010 Aug; 46(12):2324-34. PubMed ID: 20591651
[TBL] [Abstract][Full Text] [Related]
18. p53 mediates the negative regulation of MDM2 by orphan receptor TR3.
Zhao BX; Chen HZ; Lei NZ; Li GD; Zhao WX; Zhan YY; Liu B; Lin SC; Wu Q
EMBO J; 2006 Dec; 25(24):5703-15. PubMed ID: 17139261
[TBL] [Abstract][Full Text] [Related]
19. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
20. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
